InflaRx to Present at the H.C. Wainwright Global Investment Conference
May 17 2022 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company developing anti-inflammatory therapeutics by targeting the
complement system, today announced that management will give a
company presentation at the upcoming H.C. Wainwright Global
Investment Conference.
The hybrid conference will be held in person in
Miami, Florida and virtually from May 23rd to May 26th. InflaRx
will present in person on Wednesday, May 25th at 10:30 AM EDT /
4:30 PM CEST, and a live stream of the presentation will be
publicly available here. A link to a recording of the company
presentation will be posted afterwards on the InflaRx website in
the Investors - Events & Presentations section. InflaRx
management will also be available for in-person and virtual
one-on-one investor meetings during the event.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
technology to discover and develop first-in-class or best-in-class,
potent and specific inhibitors of C5a and C5aR. Complement C5a and
its receptor C5aR are powerful inflammatory mediators involved in
the progression of a wide variety of autoimmune and other
inflammatory diseases. InflaRx was founded in 2007, and the group
has offices and subsidiaries in Jena and Munich, Germany, as well
as Ann Arbor, MI, USA. For further information, please visit
www.inflarx.com.
Contacts:
InflaRx N.V.Jordan Zwick –
Chief Strategy OfficerEmail: IR@inflarx.de Tel: +1
917-338-6523
MC Services AGKatja Arnold,
Laurie Doyle, Andreas Jungfer Email: inflarx@mc-services.eu Europe:
+49 89-210 2280US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “believe,” “estimate,”
“predict,” “potential” or “continue” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and may include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, development of vilobelimab for
mechanically ventilated COVID-19 patients; future analysis of our
Phase II/III PANAMO trial and interactions with regulators
regarding the results of the trial and potential regulatory
approval pathways; the impact of the COVID-19 pandemic on us; the
timing and our ability to commence and conduct clinical trials;
potential results from current or potential future collaborations;
our ability to make regulatory filings, obtain positive guidance
from regulators, and obtain and maintain regulatory approvals for
our product candidates; our intellectual property position; our
ability to develop commercial functions; expectations regarding
clinical trial data; decisions regarding the strategic direction of
our company; our results of operations, cash needs, financial
condition, liquidity, prospects, future transactions, growth and
strategies; the industry in which we operate; the trends that may
affect the industry or us; our status as an emerging growth company
and/or foreign private issuer; and the risks, uncertainties and
other factors described under the heading “Risk Factors” in
InflaRx’s periodic filings with the Securities and Exchange
Commission. These statements speak only as of the date of this
press release and involve known and unknown risks, uncertainties
and other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024